Simulations Plus announces U.S. FDA renewed license to DILIsym platform

Simulations Plus announced that the U.S. FDA has renewed its licenses to the DILIsym software platform. DILIsym is the industry gold standard for quantitative systems toxicology, QST, software designed for the prediction and investigation of drug-induced liver injury, DILI. The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions.